Severe Infection and Risk of Cardiovascular Disease: A Multicohort Study.


Journal

Circulation
ISSN: 1524-4539
Titre abrégé: Circulation
Pays: United States
ID NLM: 0147763

Informations de publication

Date de publication:
23 05 2023
Historique:
medline: 26 5 2023
pubmed: 28 3 2023
entrez: 27 3 2023
Statut: ppublish

Résumé

The excess risk of cardiovascular disease associated with a wide array of infectious diseases is unknown. We quantified the short- and long-term risk of major cardiovascular events in people with severe infection and estimated the population-attributable fraction. We analyzed data from 331 683 UK Biobank participants without cardiovascular disease at baseline (2006-2010) and replicated our main findings in an independent population from 3 prospective cohort studies comprising 271 329 community-dwelling participants from Finland (baseline 1986-2005). Cardiovascular risk factors were measured at baseline. We diagnosed infectious diseases (the exposure) and incident major cardiovascular events after infections, defined as myocardial infarction, cardiac death, or fatal or nonfatal stroke (the outcome) from linkage of participants to hospital and death registers. We computed adjusted hazard ratios (HRs) and 95% CIs for infectious diseases as short- and long-term risk factors for incident major cardiovascular events. We also calculated population-attributable fractions for long-term risk. In the UK Biobank (mean follow-up, 11.6 years), 54 434 participants were hospitalized for an infection, and 11 649 had an incident major cardiovascular event at follow-up. Relative to participants with no record of infectious disease, those who were hospitalized experienced increased risk of major cardiovascular events, largely irrespective of the type of infection. This association was strongest during the first month after infection (HR, 7.87 [95% CI, 6.36-9.73]), but remained elevated during the entire follow-up (HR, 1.47 [95% CI, 1.40-1.54]). The findings were similar in the replication cohort (HR, 7.64 [95% CI, 5.82-10.03] during the first month; HR, 1.41 [95% CI, 1.34-1.48] during mean follow-up of 19.2 years). After controlling for traditional cardiovascular risk factors, the population-attributable fraction for severe infections and major cardiovascular events was 4.4% in the UK Biobank and 6.1% in the replication cohort. Infections severe enough to require hospital treatment were associated with increased risks for major cardiovascular disease events immediately after hospitalization. A small excess risk was also observed in the long-term, but residual confounding cannot be excluded.

Sections du résumé

BACKGROUND
The excess risk of cardiovascular disease associated with a wide array of infectious diseases is unknown. We quantified the short- and long-term risk of major cardiovascular events in people with severe infection and estimated the population-attributable fraction.
METHODS
We analyzed data from 331 683 UK Biobank participants without cardiovascular disease at baseline (2006-2010) and replicated our main findings in an independent population from 3 prospective cohort studies comprising 271 329 community-dwelling participants from Finland (baseline 1986-2005). Cardiovascular risk factors were measured at baseline. We diagnosed infectious diseases (the exposure) and incident major cardiovascular events after infections, defined as myocardial infarction, cardiac death, or fatal or nonfatal stroke (the outcome) from linkage of participants to hospital and death registers. We computed adjusted hazard ratios (HRs) and 95% CIs for infectious diseases as short- and long-term risk factors for incident major cardiovascular events. We also calculated population-attributable fractions for long-term risk.
RESULTS
In the UK Biobank (mean follow-up, 11.6 years), 54 434 participants were hospitalized for an infection, and 11 649 had an incident major cardiovascular event at follow-up. Relative to participants with no record of infectious disease, those who were hospitalized experienced increased risk of major cardiovascular events, largely irrespective of the type of infection. This association was strongest during the first month after infection (HR, 7.87 [95% CI, 6.36-9.73]), but remained elevated during the entire follow-up (HR, 1.47 [95% CI, 1.40-1.54]). The findings were similar in the replication cohort (HR, 7.64 [95% CI, 5.82-10.03] during the first month; HR, 1.41 [95% CI, 1.34-1.48] during mean follow-up of 19.2 years). After controlling for traditional cardiovascular risk factors, the population-attributable fraction for severe infections and major cardiovascular events was 4.4% in the UK Biobank and 6.1% in the replication cohort.
CONCLUSIONS
Infections severe enough to require hospital treatment were associated with increased risks for major cardiovascular disease events immediately after hospitalization. A small excess risk was also observed in the long-term, but residual confounding cannot be excluded.

Identifiants

pubmed: 36971007
doi: 10.1161/CIRCULATIONAHA.122.061183
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

1582-1593

Subventions

Organisme : Wellcome Trust
ID : 201440/Z/16/Z
Pays : United Kingdom
Organisme : NIA NIH HHS
ID : R01 AG056477
Pays : United States
Organisme : Medical Research Council
Pays : United Kingdom
Organisme : NIA NIH HHS
ID : R01 AG052519
Pays : United States

Commentaires et corrections

Type : CommentIn

Auteurs

Pyry N Sipilä (PN)

Departments of Public Health (P.N.S., J.V.L., S.T.N., J.P., M.K.).
Finnish Institute of Occupational Health, Helsinki (P.N.S., A.V., A.K., S.T.N., J.P., M.K.).

Joni V Lindbohm (JV)

Departments of Public Health (P.N.S., J.V.L., S.T.N., J.P., M.K.).
UCL Brain Sciences (J.V.L., G.D.B., M.K.), University College London, UK.

G David Batty (GD)

UCL Brain Sciences (J.V.L., G.D.B., M.K.), University College London, UK.

Nelli Heikkilä (N)

Bacteriology and Immunology and Translational Immunology Research Program, University of Helsinki, Finland (N.H., S.M.).

Jussi Vahtera (J)

Department of Public Health, University of Turku, Finland (J.V., S.S., J.P.).
Centre for Population Health Research, University of Turku and Turku University Hospital, Finland (J.V.).

Sakari Suominen (S)

Department of Public Health, University of Turku, Finland (J.V., S.S., J.P.).
Turku University Hospital, Finland (S.S.).
School of Health and Education, University of Skövde, Sweden (S.S.).

Ari Väänänen (A)

Finnish Institute of Occupational Health, Helsinki (P.N.S., A.V., A.K., S.T.N., J.P., M.K.).

Aki Koskinen (A)

Finnish Institute of Occupational Health, Helsinki (P.N.S., A.V., A.K., S.T.N., J.P., M.K.).

Solja T Nyberg (ST)

Departments of Public Health (P.N.S., J.V.L., S.T.N., J.P., M.K.).
Finnish Institute of Occupational Health, Helsinki (P.N.S., A.V., A.K., S.T.N., J.P., M.K.).

Seppo Meri (S)

Bacteriology and Immunology and Translational Immunology Research Program, University of Helsinki, Finland (N.H., S.M.).
HUSLAB, Helsinki University Hospital, Finland (S.M.).

Jaana Pentti (J)

Departments of Public Health (P.N.S., J.V.L., S.T.N., J.P., M.K.).
Finnish Institute of Occupational Health, Helsinki (P.N.S., A.V., A.K., S.T.N., J.P., M.K.).
Department of Public Health, University of Turku, Finland (J.V., S.S., J.P.).

Charlotte Warren-Gash (C)

Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, United Kingdom (C.W.-G.).

Andrew C Hayward (AC)

Institute of Epidemiology and Health Care (A.C.H.), University College London, UK.

Mika Kivimäki (M)

Departments of Public Health (P.N.S., J.V.L., S.T.N., J.P., M.K.).
Finnish Institute of Occupational Health, Helsinki (P.N.S., A.V., A.K., S.T.N., J.P., M.K.).
UCL Brain Sciences (J.V.L., G.D.B., M.K.), University College London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH